Aileron Therapeutics
281 Albany Street
Cambridge
Massachusetts
02142
United States
Tel: 617-995-0900
Fax: 617-995-2410
Website: http://www.aileronrx.com/
Email: info@aileronrx.com
86 articles with Aileron Therapeutics
-
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924
8/3/2020
Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported positive interim data from dose optimization part of study demonstrated 0.3 mg/kg dose of ALRN-6924, now being evaluated in expansion cohort, resulted in most robust chemoprotective effects
-
Clinical Catch-Up: June 29-July 3
7/6/2020
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look. -
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
Clinical Catch-Up: October 14-18
10/21/2019
Last week was busy for clinical trial news. Here’s a look. -
Clinical Catch-Up: September 23-27
9/30/2019
It was a moderately busy week for clinical trial news. Here’s a look. -
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
Billions of dollars are being invested in Boston-based life science companies.
-
The 2017 Biotech IPO Winners and Losers
12/21/2017
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs. -
Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
12/12/2017
The data were reviewed in separate oral presentations by researchers from the Dana-Farber Cancer Institute and the Albert Einstein College of Medicine during the 2017 American Society of Hematology Annual Meeting.
-
Aileron Therapeutics Reports Third Quarter 2017 Financial Results
11/10/2017
Cash, cash equivalents and investments as of September 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016.
-
Aileron Therapeutics Added To The Russell 2000, Russell 3000 And Russell Microcap Indexes
9/19/2017
-
Aileron Therapeutics Announces Presentation Of Preclinical Data With ALRN-6924 At The International Society Of Experimental Hematology Annual Scientific Meeting
8/24/2017
-
Aileron Therapeutics Reports Second Quarter 2017 Financial Results
8/11/2017
-
Aileron Therapeutics Announces Pricing Of Initial Public Offering
6/29/2017
-
Aileron Therapeutics Appoints Donald Dougherty As Senior Vice President And Chief Financial Officer
6/15/2017
-
Aileron Therapeutics Files For $69 Million IPO As New Offerings Heat Up
6/6/2017
-
Aileron Therapeutics Release: Anti-Tumor Activity Observed In Phase I Trial Of Novel P53-Targeting Drug ALRN-6924
6/5/2017
-
Aileron Therapeutics Announces Oral Presentation At ASCO On ALRN-6924 Targeting p53
5/18/2017
-
Aileron Therapeutics Initiates Phase 1 Cancer Study Of ALRN-6924 In Advanced Hematologic And Solid Malignancies With Wild Type P53
2/12/2015
-
Aileron Therapeutics Appoints Evan Lippman As Chief Financial And Business Officer
1/8/2015